772 related articles for article (PubMed ID: 32046217)
21. CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report.
Wang X; Raghavan A; Chen T; Qiao L; Zhang Y; Ding Q; Musunuru K
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):783-6. PubMed ID: 26941020
[TBL] [Abstract][Full Text] [Related]
22. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
[TBL] [Abstract][Full Text] [Related]
23. Could CRISPR be the solution for gene editing's Gordian knot?
Fang H; Wang W
Cell Biol Toxicol; 2016 Dec; 32(6):465-467. PubMed ID: 27614448
[No Abstract] [Full Text] [Related]
24. Applications of Engineered DNA-Binding Molecules Such as TAL Proteins and the CRISPR/Cas System in Biology Research.
Fujita T; Fujii H
Int J Mol Sci; 2015 Sep; 16(10):23143-64. PubMed ID: 26404236
[TBL] [Abstract][Full Text] [Related]
25. CRISPR-Cas13 Inhibitors Block RNA Editing in Bacteria and Mammalian Cells.
Lin P; Qin S; Pu Q; Wang Z; Wu Q; Gao P; Schettler J; Guo K; Li R; Li G; Huang C; Wei Y; Gao GF; Jiang J; Wu M
Mol Cell; 2020 Jun; 78(5):850-861.e5. PubMed ID: 32348779
[TBL] [Abstract][Full Text] [Related]
26. Repurposing type I-F CRISPR-Cas system as a transcriptional activation tool in human cells.
Chen Y; Liu J; Zhi S; Zheng Q; Ma W; Huang J; Liu Y; Liu D; Liang P; Songyang Z
Nat Commun; 2020 Jun; 11(1):3136. PubMed ID: 32561716
[TBL] [Abstract][Full Text] [Related]
27. Genome engineering through CRISPR/Cas9 technology in the human germline and pluripotent stem cells.
Vassena R; Heindryckx B; Peco R; Pennings G; Raya A; Sermon K; Veiga A
Hum Reprod Update; 2016 Jun; 22(4):411-9. PubMed ID: 26932460
[TBL] [Abstract][Full Text] [Related]
28. CRISPR technologies for bacterial systems: Current achievements and future directions.
Choi KR; Lee SY
Biotechnol Adv; 2016 Nov; 34(7):1180-1209. PubMed ID: 27566508
[TBL] [Abstract][Full Text] [Related]
29. Energy biotechnology in the CRISPR-Cas9 era.
Estrela R; Cate JH
Curr Opin Biotechnol; 2016 Apr; 38():79-84. PubMed ID: 26874259
[TBL] [Abstract][Full Text] [Related]
30. An overview of applications of CRISPR-Cas technologies in biomedical engineering.
Jamehdor S; Zaboli KA; Naserian S; Thekkiniath J; Omidy HA; Teimoori A; Johari B; Taromchi AH; Sasano Y; Kaboli S
Folia Histochem Cytobiol; 2020; 58(3):163-173. PubMed ID: 32978771
[TBL] [Abstract][Full Text] [Related]
31. Cas13d Is a Compact RNA-Targeting Type VI CRISPR Effector Positively Modulated by a WYL-Domain-Containing Accessory Protein.
Yan WX; Chong S; Zhang H; Makarova KS; Koonin EV; Cheng DR; Scott DA
Mol Cell; 2018 Apr; 70(2):327-339.e5. PubMed ID: 29551514
[TBL] [Abstract][Full Text] [Related]
32. Commentary - CRISPR-based techniques: Cas9, Cas13 and their applications in the era of COVID-19.
Zaami S; Piergentili R; Marinelli E; Montanari Vergallo G
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1752-1761. PubMed ID: 33629345
[TBL] [Abstract][Full Text] [Related]
33. Anti-CRISPRs: Protein Inhibitors of CRISPR-Cas Systems.
Davidson AR; Lu WT; Stanley SY; Wang J; Mejdani M; Trost CN; Hicks BT; Lee J; Sontheimer EJ
Annu Rev Biochem; 2020 Jun; 89():309-332. PubMed ID: 32186918
[TBL] [Abstract][Full Text] [Related]
34. Recent advances in CRISPR/Cas9 mediated genome editing in Bacillus subtilis.
Hong KQ; Liu DY; Chen T; Wang ZW
World J Microbiol Biotechnol; 2018 Sep; 34(10):153. PubMed ID: 30269229
[TBL] [Abstract][Full Text] [Related]
35. The genome editing revolution: A CRISPR-Cas TALE off-target story.
Stella S; Montoya G
Bioessays; 2016 Jul; 38 Suppl 1():S4-S13. PubMed ID: 27417121
[TBL] [Abstract][Full Text] [Related]
36. CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia.
Chadwick AC; Musunuru K
Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):12-18. PubMed ID: 28838920
[TBL] [Abstract][Full Text] [Related]
37. The Expanding Class 2 CRISPR Toolbox: Diversity, Applicability, and Targeting Drawbacks.
Hajizadeh Dastjerdi A; Newman A; Burgio G
BioDrugs; 2019 Oct; 33(5):503-513. PubMed ID: 31385197
[TBL] [Abstract][Full Text] [Related]
38. A jumbo phage that forms a nucleus-like structure evades CRISPR-Cas DNA targeting but is vulnerable to type III RNA-based immunity.
Malone LM; Warring SL; Jackson SA; Warnecke C; Gardner PP; Gumy LF; Fineran PC
Nat Microbiol; 2020 Jan; 5(1):48-55. PubMed ID: 31819217
[TBL] [Abstract][Full Text] [Related]
39. Functional Features and Current Applications of the RNA-Targeting Type VI CRISPR-Cas Systems.
Perčulija V; Lin J; Zhang B; Ouyang S
Adv Sci (Weinh); 2021 Jul; 8(13):2004685. PubMed ID: 34254038
[TBL] [Abstract][Full Text] [Related]
40. CRISPR-Cas9 system: A new-fangled dawn in gene editing.
Gupta D; Bhattacharjee O; Mandal D; Sen MK; Dey D; Dasgupta A; Kazi TA; Gupta R; Sinharoy S; Acharya K; Chattopadhyay D; Ravichandiran V; Roy S; Ghosh D
Life Sci; 2019 Sep; 232():116636. PubMed ID: 31295471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
